Correlation between structural properties and in vivo biocompatibility of alumina/zirconia bioceramics Simona Cavalu Simona Cavalu Professor Professor Preclinical Sciences Department Preclinical Sciences Department Faculty of Medicine and Pharmaceutics Faculty of Medicine and Pharmaceutics University of Oradea University of Oradea ROMANIA ROMANIA
21
Embed
Correlation between structural properties and in vivo biocompatibility of alumina/zirconia bioceramics
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Correlation between structural properties and in vivo
biocompatibility of alumina/zirconia bioceramics
Simona CavaluSimona Cavalu ProfessorProfessor Preclinical Sciences DepartmentPreclinical Sciences DepartmentFaculty of Medicine and PharmaceuticsFaculty of Medicine and Pharmaceutics University of OradeaUniversity of Oradea ROMANIAROMANIA
Motivation There is a continuous input from bioengineering for
reaching a high level of comfort, improving reliability, finding new applications.
This development is also a response to the growing number of patients afflicted with traumatic or non-traumatic conditions: the number of implants is continuously growing, due to the increase in persons suffering of arthritis and joint problems.
As the average age of population grows, the need for medical devices to replace damaged or worn tissues increases.
As patients have become more and more demanding regarding esthetic and biocompatibility aspects of their dental restorations
Motivation Al2O3 ZrO2
Excellent hardness and wear properties.
Fracture toughness values are lower than those of the metals used in orthopedic surgery.
Chemical and hydrothermal stability.
It is a brittle material, with low resistance to the propagation of cracks.
Was introduced to overcome the limitations of alumina.
When properly manufactured, zirconia has a higher strength, but only 50% of alumina’s hardness.
Unstable material. The tetragonal phase tends to transform into the monoclinic phase. The addition of stabilizing materials (Y2O3)during manufacture, can control the phase transformation of zirconia.
Al2O3, ZrO2, TiO2 have been considered as bioinert ceramics since they cannot induce apatite formation in SBF. They do however support bone cell attachment, proliferation and differentiation.
The ideal ceramic is a high performance biocomposite that combines the excellent material properties of alumina in terms of chemical stability and low wear and of zirconia with its superior mechanical strength and fracture toughness.
Alumina/zirconia ceramics were successfully used in total hip/knee arthroplasty in the last decades.
For dental application: root canal posts, orthodontic brackets, implant abutments and all- ceramic restaurations.
Goal
An evaluation of the structural and biocompatibility properties of a new zirconia toughened alumina ceramics.
The composition of proposed materials for this study:
90%Al2O3-10%ZrO2 and
90%Al2O3-10%ZrO2+5%TiO2
prepared by using modern processing technologies – spark plasma sintering.
Methods Investigation of the structural changes induced by TiO2
addition to Al2O3/ ZrO2 are made by FTIR spectroscopy and X-ray diffraction (XRD) analysis .
Scanning Electron Microscopy (SEM) and EDX are used for microstructure and morphology investigation of the samples.
In order to perform in vivo tests, the rat model has been applied for biocompatibility evaluation. The rat model has been accepted as a model for the effects of systemic disease on osseointegration.
SEM micrographs are recorded on the rats femur along with the elemental composition of the sheared implant surfaces at different time intervals after the surgery.
Histological examination of the connective tissue is performed to detect any immunological or inflammatory responses.
Results: XRD Spectroscopy
XRD patterns of (a) 90Al2O3∙10ZrO2 and (b) 90Al2O3∙10ZrO2 + 5%TiO2 samples.
0 10 20 30 40 50 60 70 80 90 100
0
200
400
600
800
1000
1200
T
A
AA
Z
A
A
Z
A
Z
A
A
AZ
A
A
Z
Z
Z
Z
Z
AA
A
A
A
A
A
A
A
(b)
(a)
Inte
nsity
(a
.u.)
2 theta (degrees)
T
The TiO2 addition slightly modifies the relative intensities of XRD peaks. Both samples show similar peak positions, the slight change of relative intensities of XRD peaks could be attributed to weak differences in size and shape of the crystals in these samples
This result suggest that zirconia present in the composite is, therefore, retained in the tetragonal form as alumina particles prevent the tetragonal to monoclinic transformation by matrix constraint.
FTIR Spectroscopy: (a) 90Al2O3∙10ZrO2 and
(b) 90Al2O3∙10ZrO2 + 5%TiO2 samples.
1200 1000 800 600 4000.2
0.3
0.4
0.5
0.6
518
465
564
614
660
780
797
1088
1168
(b)
(a)
Inte
nsity
(a
.u.)
Wavenumber (cm-1)
The large bands around 1088 cm-1 are assigned to stretching vibration of Al–O–Al bonds.
The Al-O stretching vibrations of tetrahedral AlO4 groups are related with the bands in the region 900 – 750 cm-1 and bands in 650 – 460 cm-1 region are associated with stretching modes of AlO6 octahedra.
The absorption bands at 518 to 564 cm-1 correspond to Zr-O vibrations in tetragonal ZrO2 phase.
Upon TiO2 addition to alumina-zirconia matrix, the relative intensity of 660/614 cm-1 band is considerably modified, as a superposition of the characteristics absorption bands occurs in this region.
SEM: Irregular shape of 90%Al2O3-10%ZrO2(a) and 90%Al2O3-10%ZrO2+5%TiO2 (b) granules and their
corresponding microstructure (c, d)
a)
b)
c)
d)
Biocompatibility evaluation: Animal model (Wistar rats)
Surgical procedure
Surgical procedure: filling the critical size
defect created in the femur
Collagen film
Monitoring the osseointegration process at different time intervals (3, 6 weeks).
Radiographic images 90Al2O3∙10ZrO2
90Al2O3∙10ZrO2 + 5%TiO2
SEM images of the sheared implant surfaces:3 weeks
90Al2O3∙10ZrO2
90Al2O3∙10ZrO2 + 5%TiO2
SEM images of the sheared implant surfaces:
6 weeks
90Al2O3∙10ZrO2
90Al2O3∙10ZrO2 + 5%TiO2
Haversian canal details
SEM Analysis reveals: Fibrinous and collagenous matrix extensively interdigitated
with the three-dimensional interconnected porous structure after first 3 weeks.
Distinct gaps between the implant and the bone were observed in a few locations.
After 6 weeks, the matrix around the surface implanted area appeared more densely, well covered and extensively integrated into a mixture of mineralized tissue, osteoid and dense matrix.
As revealed from the EDAX spectra, calcium/phosphate ratio is an indicative of the surface implant coverage for a successful osseointegration, varying from 1.5 (after 3 weeks) to 1.9 (after 6 weeks).
The results suggest that TiO2 presence in the samples favor the osseointegration process.
XRD spectrum of the femoral bone
0 20 40 60 80 100
0
100
200
300
400
500
600
700
800
900
*
*
AZAZ
AZABA
Z
A
AA
ZAZ
AZA
AA
I (a
.u.)
2 (deg)
AlZr Biocomposite
Bone/AlZr
Bone
AT
Z
B
Histological images: The connective tissue was also examined to detect any
immunological or inflammatory responses
osteoblasts
A network of woven bony trabecular architecture with cellular infiltration was observed
Conclusions Structural investigations of the proposed composites
using XRD and FTIR spectroscopy confirms the stability of the microstructure upon TiO2 addition to alumina/zirconia matrix.
In vivo: both implanted materials in critical size defect of the femur were well integrated in the original bone defects and covered with a layer of soft tissue at 6 weeks after implantation, as demonstrated by SEM images.
As revealed from the EDAX spectra, Ca/P ratio is an indicative of the surface implant coverage for a successful osseointegration, varying from 1.5 (after 3 weeks) to 1.9 (after 6 weeks).
No signs of inflammatory reactions, such as necrosis or reddening suggesting implant rejection, were found upon histological examination.
The team: Prof. dr. Gultekin Goller and dr. Ipek Akin, Istanbul
Prof. dr. Viorica Simon and dr. Oana Ponta Babes-Bolyai University, Faculty of Physics & Institute of Interdisciplinary Research in Bio-Nano-Sciences, Cluj-Napoca, Romania.
Assoc. prof. Cristian Ratiu and dr. Ioan Oswald University of Oradea, Faculty of Medicine and Pharmaceutics, Oradea, Romania.